ライフサイエンスコーパス: intravenous immunoglobulin

1 rs for the purpose of developing hyperimmune intravenous immunoglobulin.

2 cal agents such as infliximab, rituximab and intravenous immunoglobulin.

3 rm was searched in combination with the term intravenous immunoglobulin.

4 imus, pimecrolimus, and imiquimod as well as intravenous immunoglobulin.

5 s of natural human IgG antibodies present in intravenous immunoglobulin.

6 id not respond to treatment with steroids or intravenous immunoglobulin.

7 et of response is slower than that seen with intravenous immunoglobulin.

8 tivity was promptly reversed with additional intravenous immunoglobulin.

9 nd ecchymoses, and recovered after receiving intravenous immunoglobulin.

10 the majority of cases reporting success with intravenous immunoglobulin.

11 reduction of immunosuppression, and frequent intravenous immunoglobulin.

12 o 7 days after completion of the infusion of intravenous immunoglobulin.

13 eroids in addition to plasma exchange and/or intravenous immunoglobulin.

14 inating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.

15 Of those treated, 99% were treated with intravenous immunoglobulin.

16 asculitis that is treated with high doses of intravenous immunoglobulin.

17 rly axonal involvement, and poor response to intravenous immunoglobulin.

18 h groups received dopamine or dobutamine and intravenous immunoglobulin.

19 idofovir, leflunomide, fluoroquinolones, and intravenous immunoglobulins.

20 were observed for other therapies, including intravenous immunoglobulins.

21 at 3-week intervals, PPH (6x), and high-dose intravenous immunoglobulin (1.5 g/kg).

22 If not treated early with high-dose intravenous immunoglobulin, 1 in 5 children develop coro

23 Combination therapy included intravenous immunoglobulin (4 cases), interferon (3 case

24 Treatment with intravenous immunoglobulins (a preparation that containe

25 The mechanisms of intravenous immunoglobulin action are complex and, for s

26 Intravenous immunoglobulin administration enhanced these

27 Moreover, in both cases intravenous immunoglobulins allowed full neutrophil coun

28 osal bleeding at diagnosis or treatment with intravenous immunoglobulin alone developed chronic ITP l

29 is regimen, the next step is the addition of intravenous immunoglobulin although this is not supporte

30 rugs, including biologic therapy, as well as intravenous immunoglobulin, although results have been m

31 nduced by injection of heat-aggregated human intravenous immunoglobulin and active systemic anaphylax

32 addition of infliximab to standard therapy (intravenous immunoglobulin and aspirin) in acute Kawasak

33 New treatments showing promise include intravenous immunoglobulin and biological agents and tri

34 ously published trials evaluating the use of intravenous immunoglobulin and colony-stimulating factor

35 Plasma exchange, intravenous immunoglobulin and corticosteroids continue

36 Intravenous immunoglobulin and corticosteroids were effe

37 nd address the role of fluorinated steroids, intravenous immunoglobulin and hydroxychloroquine for pr

38 re incubated on glass coverslips coated with intravenous immunoglobulin and inactive complement compo

39 A partial response to intravenous immunoglobulin and other treatments is repor

40 In MMNCB adequate comparative studies of intravenous immunoglobulin and plasma exchange have not

41 proved after chemotherapy and treatment with intravenous immunoglobulin and prednisone.

42 Desensitization with intravenous immunoglobulin and rituximab (I+R) significa

43 estigated the effect of desensitization with intravenous immunoglobulin and rituximab on the antibody

44 f four plasmapheresis treatments followed by intravenous immunoglobulin and splenectomy at the time o

45 ition was not treated with plasmapheresis or intravenous immunoglobulin and was not associated with p

46 Treatment with glucocorticoids-less so with intravenous immunoglobulins and plasma exchange-was asso

47 For 2 years, the patient was treated with intravenous immunoglobulins and steroids, with partial i

48 ral arm of the immune system by using either intravenous immunoglobulins and/or immunoadsorption will

49 ve therapy (azathioprine or methotrexate and intravenous immunoglobulin) and had normalization of str

50 ith antitumor necrosis factor agents, pooled intravenous immunoglobulin, and anti-B-cell therapies su

51 (using plasmapheresis followed by 100 mg/kg intravenous immunoglobulin, and anti-CD20 antibody), and

52 rolled in a trial comparing plasma exchange, intravenous immunoglobulin, and both treatments.

53 nts, and was reversible with plasmapheresis, intravenous immunoglobulin, and increasing immunosuppres

54 nsisted of plasma exchange, corticosteroids, intravenous immunoglobulin, and other immunosuppressive

55 He was treated with antibiotics, intravenous immunoglobulin, and oxygen by nasal cannula.

56 of RSV infections are limited to ribavirin, intravenous immunoglobulin, and palivizumab.

57 Anticoagulation, corticosteroids, intravenous immunoglobulin, and plasma exchange are the

58 nefit, are immunosuppressive drugs, danazol, intravenous immunoglobulin, and plasma exchange.

59 ination of anticoagulation, corticosteroids, intravenous immunoglobulin, and plasma exchange; there i

60 immunomodulatory agents including steroids, intravenous immunoglobulin, and plasmapheresis have show

61 yte antigen antibodies using plasmapheresis, intravenous immunoglobulin, and rituximab has been repor

62 ived previous treatment with plasmapheresis, intravenous immunoglobulin, and rituximab that was ineff

63 Despite treatment with immunepheresis, intravenous immunoglobulin, and rituximab, and in some c

64 combined with pretransplant plasmapheresis, intravenous immunoglobulin, and splenectomy.

65 ing plasmapheresis preconditioning, low-dose intravenous immunoglobulin, and standard maintenance imm

66 e prophylaxis with steroids, pentoxifylline, intravenous immunoglobulin, and total body irradiation).

67 pies including corticosteroids, splenectomy, intravenous immunoglobulin, and various cytotoxic or imm

68 e impossible for mycophenolate, montelukast, intravenous immunoglobulins, and systemic glucocorticost

69 responses to treatment with glucocorticoids, intravenous immunoglobulins, and/or plasma exchange at s

70 patients received intravenous steroids; 43, intravenous immunoglobulin; and 13, plasma exchange; or

71 of the underling inflammatory condition with intravenous immunoglobulin, anti TNF agents, thalidomide

72 been suggested, including administration of intravenous immunoglobulin, apheresis, and combination t

73 manage, but antimalarials, methotrexate, and intravenous immunoglobulin are effective in small, often

74 Children who do not respond to intravenous immunoglobulin are the focus of trials to mi

75 Intravenous immunoglobulin as treatment of ocular cicatr

76 hylactic therapies, including treatment with intravenous immunoglobulin, await larger trials.

77 r to those seen in treatment with polyclonal intravenous immunoglobulin, but anemia requiring blood t

78 ivalent efficacy of both plasma exchange and intravenous immunoglobulin, but not corticosteroids, in

79 tients improve with GABA-enhancing drugs and intravenous immunoglobulin, but some respond poorly and

80 trate that the anti-inflammatory activity of intravenous immunoglobulin can be recapitulated by the t

81 econdary causes, we treated the patient with intravenous immunoglobulin, considering primary neuromyo

82 g therapies, including glucocorticosteroids, intravenous immunoglobulins, cyclosporine, plasmapheresi

83 rticotropin hormone, corticosteroids, and/or intravenous immunoglobulin, develop long-term neurologic

84 Aerosolized ribavirin with or without intravenous immunoglobulin did not appear to alter morta

85 Intravenous immunoglobulin effectively diminished platel

86 ethylprednisolone for 5 days, 0.4 mg/kg/d of intravenous immunoglobulin for 5 days, and 2 doses of ri

87 rdiography is a criterion for treatment with intravenous immunoglobulin for incomplete Kawasaki disea

88 s and 1.3 mg/m(2) bortezomib; then 0.5 mg/kg intravenous immunoglobulin four times.

89 Finally, we showed that intravenous immunoglobulin G (IVIG) treatment significan

90 by individual human sera or by pooled human, intravenous immunoglobulin G (IVIG) were dispersed over

91 osomes (n=2) or commercially available human intravenous immunoglobulin G depleted of anti-Gal Ab (n=

92 Intravenous immunoglobulin G results in resolution of an

93 aggressive management with corticosteroids, intravenous immunoglobulin G, or anti-D immune globulin.

94 reductions in immunosuppressive medication, intravenous immunoglobulin, ganciclovir, and rituximab.

95 Despite the use of plasma exchanges and intravenous immunoglobulins, Guillain-Barre syndrome (GB

96 charide 1 associated with the Fc fragment of intravenous immunoglobulin has been synthesized.

97 usion of convalescent plasma (or hyperimmune intravenous immunoglobulin) has been reported to be an e

98 xisting therapeutics such as the delivery of intravenous immunoglobulin have led to interest in devel

99 esponses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized.

100 mune anti-human immunodeficiency virus (HIV) intravenous immunoglobulin (HIVIG) were evaluated in the

101 a mouse model of EV-D68 infection: (1) human intravenous immunoglobulin (hIVIG), (2) fluoxetine, and

102 investigate the effect of Thymoglobulin and intravenous immunoglobulin (i.v.IG) therapy on the clini

103 Further, human intravenous immunoglobulin (i.v.Ig), now a standard trea

104 unodeficiency (PI) is equally efficacious to intravenous immunoglobulin (IGIV), induces fewer systemi

105 -term follow-up data received immunotherapy (intravenous immunoglobulin in 10 and corticosteroids and

106 e from randomized trials supports the use of intravenous immunoglobulin in Guillain-Barre syndrome, c

107 Resistance to intravenous immunoglobulin in Kawasaki disease increases

108 Only one, using intravenous immunoglobulin in refractory dermatomyositis

109 ramer acetate in primary progressive MS, and intravenous immunoglobulin in secondary progressive MS).

110 thymoglobulin induction, plasmapheresis, and intravenous immunoglobulin in the highest risk groups.

111 echanisms of action, efficacy, and safety of intravenous immunoglobulins in rheumatic diseases demons

112 espectively, with antithymocyte globulin and intravenous immunoglobulin induction treatment.

113 stored sera from 254 infected children in an intravenous immunoglobulin infection prophylaxis trial.

114 ressive protocol consisted of plasmapheresis/intravenous immunoglobulin infusion before LDLT followed

115 No reactions to intravenous immunoglobulin infusion occurred in patients

116 on of immunosuppression, oral acyclovir, and intravenous immunoglobulin injection.

117 vel anti-metabolites; combination therapies; intravenous immunoglobulin; intravitreally inserted cort

118 Intravenous immunoglobulin is a reasonable short-term tr

119 High-dose intravenous immunoglobulin is a widely used therapeutic

120 ry aneurysms; this risk is reduced 5-fold if intravenous immunoglobulin is administered within 10 day

121 Intravenous immunoglobulin is already a standard therapy

122 bocytopenic bleeding in the third trimester, intravenous immunoglobulin is an appropriate first-line

123 Intravenous immunoglobulin is effective in many autoimmu

124 In Guillain-Barre syndrome and CIDP intravenous immunoglobulin is equivalent to but more con

125 enolate mofetil, dehydroepiandrosterone, and intravenous immunoglobulin is increasing, but plasmapher

126 Intravenous immunoglobulin is not effective in patients

127 Intravenous immunoglobulin is not only effective for the

128 The protective effect of intravenous immunoglobulin is remarkable and needs confi

129 This anti-inflammatory activity of intravenous immunoglobulin is triggered by a minor popul

130 Intravenous immunoglobulin is used as a replacement ther

131 phosphamide combined with plasmapheresis and intravenous immunoglobulins is an option for patients wi

132 infants born to mothers following antenatal intravenous immunoglobulin (IVIG) +/- prednisone therapy

133 Intravenous immunoglobulin (IVIG) and aspirin is the sta

134 rtiary centers compared the effectiveness of intravenous immunoglobulin (IVIg) and corticosteroids in

135 ctiveness of desensitization using high-dose intravenous immunoglobulin (IVIG) and rituximab to impro

136 e than 5 years to investigate the effects of intravenous immunoglobulin (IVIG) and rituximab treatmen

137 Intravenous immunoglobulin (IVIG) are purified IgG prepa

138 reatment unnecessarily; there was overuse of intravenous immunoglobulin (IVIg) as first-line therapy

139 anaphylactoid reactions on administration of intravenous immunoglobulin (IVIg) associated with the pr

140 Administration of intravenous immunoglobulin (IVIg) can prevent uptake, bu

141 Intravenous immunoglobulin (IVIG) concentrates were orig

142 of administering during pregnancy high-dose intravenous immunoglobulin (IVIG) derived from pooled se

143 Despite the success of intravenous immunoglobulin (IVIg) desensitization to red

144 neglobulin (anti-D) and 6 of 8 responding to intravenous immunoglobulin (IVIG) did not have correspon

145 Intravenous immunoglobulin (IVIG) enhances immune homeos

146 trial showed short and long-term efficacy of intravenous immunoglobulin (IVIG) for the treatment of C

147 Commercial intravenous immunoglobulin (IVIG) given before the infla

148 Intravenous immunoglobulin (IVIG) has been shown to have

149 Intravenous immunoglobulin (IVIg) has been used in the t

150 evels and improvement of transplant rates by intravenous immunoglobulin (IVIG) in a randomized, doubl

151 were conducted to investigate the effects of intravenous immunoglobulin (IVIG) in a rat model of immu

152 nized paradigm for the therapeutic action of intravenous immunoglobulin (IVIG) in immune thrombocytop

153 espite the beneficial therapeutic effects of intravenous immunoglobulin (IVIg) in inflammatory diseas

154 Given the known efficacy of intravenous immunoglobulin (IVIg) in the treatment of ch

155 The use of clindamycin and intravenous immunoglobulin (IVIG) in treatment of invasi

156 We sought to determine whether intravenous immunoglobulin (IVIg) induces a nonresponsiv

157 e after controlled trials with three monthly intravenous immunoglobulin (IVIg) infusions.

158 Intravenous immunoglobulin (IVIG) is a FDA-approved drug

159 Intravenous immunoglobulin (IVIG) is a frequently used d

160 Intravenous immunoglobulin (IVIg) is a polyclonal IgG pr

161 Intravenous immunoglobulin (IVIG) is a purified pool of

162 The antiinflammatory activity of intravenous immunoglobulin (IVIG) is dependent on the pr

163 Intravenous immunoglobulin (IVIG) is sometimes administe

164 Intravenous immunoglobulin (IVIG) is the treatment of ch

165 ith rabbit antithymocyte globulin (RATG) and intravenous immunoglobulin (IVIG) may allow successful t

166 Two small trials suggest that low-dose intravenous immunoglobulin (IVIg) may improve the sympto

167 To determine the effect of intravenous immunoglobulin (IVIG) on brain atrophy and c

168 ntibodies received monthly courses of either intravenous immunoglobulin (IVIg) or plasmapheresis, in

169 High-dose intravenous immunoglobulin (IVIG) prevents immune damage

170 Intravenous immunoglobulin (IVIG) products are derived f

171 althy people and routinely in pharmaceutical intravenous immunoglobulin (IVIG) purified from serum po

172 Plasmapheresis (PP) and intravenous immunoglobulin (IVIg) remove donor-specific

173 IgG-Fc receptor gene FcgammaRIIB influences intravenous immunoglobulin (IVIG) response in Kawasaki d

174 cytic cells, and a commercial preparation of intravenous immunoglobulin (IVIG) served as the source o

175 Treatment with high-dose (400 mg/kg/day) intravenous immunoglobulin (IVIg) shows benefit in many

176 All patients received intravenous immunoglobulin (IVIG) therapy at 400 mg/kg x

177 rpose of this study was to determine whether intravenous immunoglobulin (IVIG) therapy could prevent

178 Intravenous immunoglobulin (IVIg) therapy effectively tr

179 Intravenous immunoglobulin (IVIG) therapy has been sugge

180 Intravenous immunoglobulin (IVIG) therapy has prevented

181 We evaluated the efficacy of intravenous immunoglobulin (IVIG) therapy in patients wi

182 Intravenous immunoglobulin (IVIg) therapy is used to tre

183 Intravenous immunoglobulin (IVIG) therapy, by virtue of

184 patient received one plasmapheresis (PP) and intravenous immunoglobulin (IVIg) treatment, anti-CD25,

185 ers as well as fetal inflammatory responses, intravenous immunoglobulin (IVIG) was evaluated as preve

186 provement on the disability grade scale with intravenous immunoglobulin (IVIg) was very similar to th

187 ith AHR treated with plasmapheresis (PP) and intravenous immunoglobulin (IVIG) with allograft surviva

188 compared with treatment with zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody.

189 Intravenous immunoglobulin (IVIG), a pooled normal IgG f

190 Intravenous immunoglobulin (IVIg), a therapeutic prepara

191 olysis, and cumulative doses of steroids and intravenous immunoglobulin (IVIG), and ameliorates neuro

192 refractory to steroids, intravenous anti-D, intravenous immunoglobulin (IVIG), and splenectomy.

193 ents, such as glucocorticoids, vitamin D, or intravenous immunoglobulin (IVIG), are discussed, as the

194 ioperative treatment with plasmapheresis and intravenous immunoglobulin (IVIG), combined with a tacro

195 Other options include plasmapheresis and intravenous immunoglobulin (IVIg), coupled with cytotoxi

196 The US Food and Drug Administration approved intravenous immunoglobulin (IVIg), extracted from the pl

197 tandard practice, aerosolized ribavirin plus intravenous immunoglobulin (IVIG), is extremely expensiv

198 tem (RES) using medronate liposomes (MLs) or intravenous immunoglobulin (IVIg), respectively.

199 otrexate antibody (AMI)-coated liposomes and intravenous immunoglobulin (IVIG)-coated liposomes (15,

200 ernal-infant pairs enrolled in a randomized, intravenous immunoglobulin (IVIG)-controlled trial of HI

201 for the anti-inflammatory activity of human intravenous immunoglobulin (IVIG).

202 serum, and commercial preparations of pooled intravenous immunoglobulin (IVIg).

203 been reported after treatment with high-dose intravenous immunoglobulin (IVIg).

204 ed intravenously or intranasally with P4 and intravenous immunoglobulin (IVIG).

205 ude a combination of plasmapheresis (PL) and intravenous immunoglobulin (IVIG).

206 flammatory diseases in the form of high-dose intravenous immunoglobulin (IVIG).

207 latory treatments such as plasma exchange or intravenous immunoglobulin (IVIG).

208 These patients were treated with intravenous immunoglobulin (IVIG).

209 ar epitopes of specified binding affinity to Intravenous Immunoglobulin (IVIg).

210 were abrogated by maternal administration of intravenous immunoglobulin (IVIG).

211 ns, we studied human serum albumin (HSA) and intravenous immunoglobulin (IVIG).

212 damage treated with a protocol of high-dose intravenous immunoglobulin (IVIG).

213 and outcome of GBS in patients treated with intravenous immunoglobulin (IVIG).

214 is of HBV serology in 16 patients commencing intravenous immunoglobulin (IVIG); and pre- and post-inf

215 n G (IgG) purified from pooled human plasma [intravenous immunoglobulin (IVIG)] confer anti-inflammat

216 We developed an intravenous immunoglobulins (IVIg) based desensitization

217 Human intravenous immunoglobulins (IVIG) have been used as an

218 pretreatment and 1 year after treatment with intravenous immunoglobulin [IVIG]) from 26 children with

219 have shown that pooled human gammaglobulin (intravenous immunoglobulin [IVIG]) inhibits the mixed ly

220 ingent selection with pooled human antisera (intravenous immunoglobulin [IVIG]) then led to the selec

221 s among plasma donors, which is reflected in intravenous immunoglobulins (IVIGs).

222 Both plasmapheresis and intravenous immunoglobulin may be employed as treatment,

223 Short-term studies suggest that intravenous immunoglobulin might reduce disability cause

224 the immune system of the neonate, including: intravenous immunoglobulins, myeloid hematopoietic growt

225 Treatment included corticosteroids (n = 7), intravenous immunoglobulin (n = 3), and plasma exchange

226 rapy consisted of steroids (n = 61/74; 82%), intravenous immunoglobulins (n = 71/74; 96%), and plasma

227 y [cPRA], 34%-99%), desensitization included intravenous immunoglobulin on days 0 and 30 and a single

228 Intravenous immunoglobulin, one promising therapy for SC

229 consensus was reached concerning the use of intravenous immunoglobulin or corticosteroids as first-l

230 immunoglobulin in 10 and corticosteroids and intravenous immunoglobulin or other immunosuppressors in

231 lled in the larger study where they received intravenous immunoglobulin or placebo as intervention.

232 or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 mon

233 Treatment with intravenous immunoglobulin or plasma exchange is the opt

234 within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 w

235 uced demyelinating neuropathy may respond to intravenous immunoglobulin or plasmapheresis.

236 d major bleeding episodes; none responded to intravenous immunoglobulin or prednisone.

237 with a combination of methylprednisolone and intravenous immunoglobulin (OR 2.67, 95% CI 1.44-4.96).

238 esection and immunotherapy (corticosteroids, intravenous immunoglobulin, or plasma exchange) respond

239 ponded to corticosteroids, cyclophosphamide, intravenous immunoglobulins, or plasmapheresis.

240 Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunos

241 on protocol starting at day 0 with high-dose intravenous immunoglobulin, plasma exchanges, and eventu

242 included first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line

243 blood group incompatible transplant using an intravenous immunoglobulin/plasmapheresis preconditionin

244 more than four pretransplant plasmapheresis/intravenous immunoglobulin (PP/IVIg) had a greater likel

245 ines in producing a functional, high-titered intravenous immunoglobulin preparation for clinical use.

246 Treatment of the ITP mice with 2 g/kg intravenous immunoglobulin raised the platelet counts, r

247 rior descending coronary artery Z score, and intravenous immunoglobulin reaction rates.

248 or in combination with either palivizumab or intravenous immunoglobulin, remains controversial.

249 ee of nine subjects were able to discontinue intravenous immunoglobulin replacement therapy.

250 he sample size and our practice of exogenous intravenous immunoglobulin replacement.

251 gular blood transfusion, iron chelation, and intravenous immunoglobulin replacement.

252 underwent treatment with corticosteroids and intravenous immunoglobulin, resulting in clinical improv

253 unosuppression, plasmapheresis, and low-dose intravenous immunoglobulin+/-rituximab.

254 Immunomodulatory protocols including intravenous immunoglobulin/rituximab (IVIG/R) are employ

255 gents, such as steroids, plasmapheresis, and intravenous immunoglobulin, seem to offer substantial im

256 Intravenous immunoglobulin seems to be beneficial in sev

257 This substudy of the larger intravenous immunoglobulin study only involved data anal

258 There is no simple answer to the question: intravenous immunoglobulin-take it or leave it?

259 to a third of KD patients fail to respond to intravenous immunoglobulin, the standard therapy, and al

260 From November 2002 to November 2004, intravenous immunoglobulin therapy (IVIG) was administer

261 He also received intravenous immunoglobulin therapy and his vision has st

262 exception of juvenile rheumatoid arthritis, intravenous immunoglobulin therapy appeared ineffective

263 e antibodies must be in some doubt, although intravenous immunoglobulin therapy has been shown to be

264 anti-inflammatory properties associated with intravenous immunoglobulin therapy require the sialic ac

265 and a lack of response to corticosteroid and intravenous immunoglobulin therapy, a 3-day course of pl

266 itioning regimen using plasmapheresis and/or intravenous immunoglobulin therapy, but underlying mecha

267 oved, new, and controversial indications for intravenous immunoglobulin therapy, with special emphasi

268 by plasmapheresis (PPH) in conjunction with intravenous immunoglobulin therapy.

269 ibodies were affinity purified by passage of intravenous immunoglobulin through purified, type-specif

270 High-dose intravenous immunoglobulin thus exploits an endogenous f

271 d with thymocytes from ITP mice treated with intravenous immunoglobulin, thymocytes from untreated IT

272 treated with corticosteroids in addition to intravenous immunoglobulin to improve their outcomes.

273 randomized, controlled trial of prophylactic intravenous immunoglobulin to prevent ICU-associated inf

274 Intravenous immunoglobulin treatment has been beneficial

275 Within a week, intravenous immunoglobulin treatment in children with ne

276 Although a pulse steroid and intravenous immunoglobulin treatment regimen was given,

277 nd CAA had longer fever duration and delayed intravenous immunoglobulin treatment time.

278 h definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible.

279 otection, as well as the limited efficacy of intravenous immunoglobulin treatments against human dise

280 nced by immunoglobulin production, decreased intravenous immunoglobulin use, and antibody response af

281 d first-line immunotherapy with steroids and intravenous immunoglobulins vs. late immunotherapy), and

282 In an attempt to decrease the PRA, intravenous immunoglobulin was given at 3-week intervals

283 Therapy with acyclovir or intravenous immunoglobulin was not correlated with lower

284 ble regimes of steroids, plasma exchange and intravenous immunoglobulin were associated with variable

285 though a consensus agreed that biologics and intravenous immunoglobulin were considered appropriate i

286 The anti-inflammatory drug high-dose intravenous immunoglobulin, widely used to suppress infl

287 ki disease (KD) and 5% of those treated with intravenous immunoglobulin will develop coronary artery

288 Both responded to intravenous immunoglobulin, with a decrease in their tit

289 e patients were treated with steroids and/or intravenous immunoglobulin, with variable positive respo